Table A. 2.

Baseline patients and tumor characteristics

Cohort	Evaluation cohort (N=244) FIRE-3, FOLFIRI+CET arm		Control cohort (N=247) FIRE-3, FOLFIRI+BEV arm		P value *
	N	%	N	%
Sex
Male	169	69	162	66	0.38
Female	75	31	85	34
Age (year)
Median (range)	64 (38–79)		65 (31–76)
≤ 65	130	53	130	53	0.89
> 65	114	47	117	47
ECOG Performance status
ECOG 0	124	51	133	54	0.50
ECOG 1–2	120	49	114	46
Primary tumor site
Right	45	18	62	25	0.070
Left	194	80	179	72
Unknown	5	2	6	2
Liver metastasis
Yes	84	34	81	33	0.70
No	160	66	166	67
Lung metastasis
Yes	94	39	94	38	0.92
No	150	61	153	62
Number of metastases
0–1	105	43	107	43	0.95
≥ 2	139	57	140	57
Primary tumor resected
Yes	203	83	213	86	0.47
No	39	16	34	14
Unknown	2	1	0	0
Adjuvant history
Yes	50	20	45	18	0.49
No	192	79	202	82
Unknown	2	1	0	0
RAS status
Wild-type	192	79	199	81	0.64
Mutant	38	16	35	14
Unknown	14	6	13	5
BRAF status					0.78
Wild-type	214	88	214	87
Mutant	22	9	24	10
Unknown	8	3	9	4

^*P value was based on Chi-square test, or the Wilcoxon test when appropriate.